Neuroprotective Properties of Green Tea () in Parkinson's Disease: A Review

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2020 Sep 2

PMID 32867388

Citations 29

Authors

Dicson Sheeja Malar

Mani Iyer Prasanth

James Michael Brimson

Rajasekharan Sharika

Bhagavathi Sundaram Sivamaruthi

Chaiyavat Chaiyasut

Tewin Tencomnao

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative disease is a collective term given for the clinical condition, which results in progressive degeneration of neurons and the loss of functions associated with the affected brain region. Apart from the increase in age, neurodegenerative diseases are also partly affected by diet and lifestyle practices. Parkinson's disease (PD) is a slow onset neurodegenerative disorder and the second most common neurodegenerative disease, which affects the motor system. Although there is no prescribed treatment method to prevent and cure PD, clinical procedures help manage the disease symptoms. Green tea polyphenols are known for several health benefits, including antioxidant, anti-inflammatory, and neuroprotective activity. The current manuscript summarizes the possible mechanisms of neuroprotective potential of green tea with a special focus on PD. Studies have suggested that the consumption of green tea protects against free-radicals, inflammation, and neuro-damages. Several in vivo studies aid in understanding the overall mechanism of green tea. However, the same dose may not be sufficient in humans to elicit similar effects due to complex physiological, social, and cultural development. Future research focused on more clinical trials could identify an optimum dose that could impart maximum health benefits to impart neuroprotection in PD.

Citing Articles

NaCTR: Natural product-derived compound-based drug discovery pipeline from traditional oriental medicine by search space reduction.

Jung S, Kim K, Wang S, Han M, Lee D Comput Struct Biotechnol J. 2024; 23:3869-3877.

PMID: 39554615 PMC: 11564001. DOI: 10.1016/j.csbj.2024.10.035.

Neurodegenerative diseases and catechins: (-)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress.

Li S, Wang Z, Liu G, Chen M Front Nutr. 2024; 11:1425839.

PMID: 39149548 PMC: 11326534. DOI: 10.3389/fnut.2024.1425839.

Polyphenols: Secondary Metabolites with a Biological Impression.

Bolat E, Saritas S, Duman H, Eker F, Akdasci E, Karav S Nutrients. 2024; 16(15).

PMID: 39125431 PMC: 11314462. DOI: 10.3390/nu16152550.

Gut-Brain Axis in Focus: Polyphenols, Microbiota, and Their Influence on α-Synuclein in Parkinson's Disease.

Riegelman E, Xue K, Wang J, Tang L Nutrients. 2024; 16(13).

PMID: 38999791 PMC: 11243524. DOI: 10.3390/nu16132041.

Role of Epigenetic Modulation in Neurodegenerative Diseases: Implications of Phytochemical Interventions.

Prasanth M, Sivamaruthi B, Cheong C, Verma K, Tencomnao T, Brimson J Antioxidants (Basel). 2024; 13(5).

PMID: 38790711 PMC: 11118909. DOI: 10.3390/antiox13050606.

References

Batista-Nascimento L, Pimentel C, Menezes R, Rodrigues-Pousada C . Iron and neurodegeneration: from cellular homeostasis to disease. Oxid Med Cell Longev. 2012; 2012:128647. PMC: 3369498. DOI: 10.1155/2012/128647. View

Cooper J, Sagar H, Jordan N, Harvey N, Sullivan E . Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 1991; 114 ( Pt 5):2095-122. DOI: 10.1093/brain/114.5.2095. View

Devi L, Raghavendran V, Prabhu B, Avadhani N, Anandatheerthavarada H . Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008; 283(14):9089-100. PMC: 2431021. DOI: 10.1074/jbc.M710012200. View

Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

Przedborski S, Kostic V, Jackson-Lewis V, Naini A, Simonetti S, Fahn S . Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci. 1992; 12(5):1658-67. PMC: 6575882. View

Tong J, Rathitharan G, Meyer J, Furukawa Y, Ang L, Boileau I . Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain. 2017; 140(9):2460-2474. PMC: 6669411. DOI: 10.1093/brain/awx172. View

Kim J, Kim J, O J, Jeon B . Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Clin Neurosci. 2010; 17(9):1165-8. DOI: 10.1016/j.jocn.2010.01.042. View

Li Q, Zhao H, Zhang Z, Liu Z, Pei X, Wang J . Long-term administration of green tea catechins prevents age-related spatial learning and memory decline in C57BL/6 J mice by regulating hippocampal cyclic amp-response element binding protein signaling cascade. Neuroscience. 2009; 159(4):1208-15. DOI: 10.1016/j.neuroscience.2009.02.008. View

Hubble J, Cao T, Hassanein R, Neuberger J, Koller W . Risk factors for Parkinson's disease. Neurology. 1993; 43(9):1693-7. DOI: 10.1212/wnl.43.9.1693. View

10.

Lees A, Smith E . Cognitive deficits in the early stages of Parkinson's disease. Brain. 1983; 106 (Pt 2):257-70. DOI: 10.1093/brain/106.2.257. View

11.

Prasanth M, Sivamaruthi B, Chaiyasut C, Tencomnao T . A Review of the Role of Green Tea () in Antiphotoaging, Stress Resistance, Neuroprotection, and Autophagy. Nutrients. 2019; 11(2). PMC: 6412948. DOI: 10.3390/nu11020474. View

12.

Xu Q, Langley M, Kanthasamy A, Reddy M . Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease. J Nutr. 2017; 147(10):1926-1931. PMC: 5610551. DOI: 10.3945/jn.117.255034. View

13.

Liu J, Zhou L, Wang Y, Wang X, Zhou Y, Ho W . Neuroprotective Activity of (-)-Epigallocatechin Gallate against Lipopolysaccharide-Mediated Cytotoxicity. J Immunol Res. 2016; 2016:4962351. PMC: 4844887. DOI: 10.1155/2016/4962351. View

14.

Aoyama K, Wang F, Matsumura N, Kiyonari H, Shioi G, Tanaka K . Increased neuronal glutathione and neuroprotection in GTRAP3-18-deficient mice. Neurobiol Dis. 2012; 45(3):973-82. DOI: 10.1016/j.nbd.2011.12.016. View

15.

Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell A, Isacson O . Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation. 2004; 1(1):6. PMC: 483059. DOI: 10.1186/1742-2094-1-6. View

16.

de Lau L, Breteler M . Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-9. View

17.

Cavanaugh J, Jaumotte J, Lakoski J, Zigmond M . Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J Neurosci Res. 2006; 84(6):1367-75. DOI: 10.1002/jnr.21024. View

18.

Ogura R, Ikeda N, Yuki K, Morita O, Saigo K, Blackstock C . Genotoxicity studies on green tea catechin. Food Chem Toxicol. 2008; 46(6):2190-200. DOI: 10.1016/j.fct.2008.02.016. View

19.

Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman E, Mizuno Y . Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A. 1996; 93(7):2696-701. PMC: 39693. DOI: 10.1073/pnas.93.7.2696. View

20.

Martin L, Pan Y, Price A, Sterling W, Copeland N, Jenkins N . Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006; 26(1):41-50. PMC: 6381830. DOI: 10.1523/JNEUROSCI.4308-05.2006. View